

MEDIMMUNE INC /DE  
Form 8-K  
August 31, 2004

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549**

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)  
August 25, 2004

**MedImmune, Inc.**  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	0-19131 (Commission File No.)	52-1555759 (I.R.S. Employer Identification No.)
One MedImmune Way, Gaithersburg, MD 20878 (Address of principal executive offices) (Zip Code)		

Registrant's telephone number, including area code (301) 398-0000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.05 Amendments to the Registrant's Code of Ethics**

On August 25, 2004, MedImmune, Inc. (the Registrant) adopted amendments to its Global Standards of Business Conduct and Ethics (the Code of Ethics) which is a code of ethics consistent with Item 406(b) of Regulation S-K. The substantive amendments (a) provide that the Code of Ethics will be monitored by the Board of Directors with the assistance of management and (b) prohibit transactions between the Company and persons subject to the Code of Ethics, or their related parties, where such person would receive or would likely receive an improper benefit as a result. A copy of the Code of Ethics, as adopted by the Registrant on August 25, 2004, is attached as Exhibit 14.

**Item 9.01 Financial Statements and Exhibits.**

(c)

<u>Exhibit No.</u>	<u>Description</u>
14	Global Standards of Business Conduct and Ethics, as adopted by the Registrant on August 25, 2004

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MedImmune, Inc.**

BY: /s/ William C. Bertrand, Jr.

William C. Bertrand, Jr.  
Vice President, General Counsel and Secretary

Dated: August 31, 2004